Chair: Vallerie V. McLaughlin

1:00 PM
Welcome and Introduction
Vallerie V. McLaughlin

1:05 PM
Perilous Pathways in PAH: Pathogenic Mediators And Treatment Targets
Milton Packer

1:25 PM
Questions and Answers with Audience Response

1:35 PM
Hemodynamic Assessment of PH: Echocardiography vs. Catheterization
Paul R. Forfia

1:55 PM
Questions and Answers with Audience Response

2:05 PM
Treatment of PAH: Establishing Goals to Optimize Outcomes
Vallerie V. McLaughlin

2:25 PM
Questions and Answers with Audience Response

2:35 PM
Evaluation and Management of Acute Decompensated Right Heart Failure
Teresa De Marco

2:55 PM
Questions and Answers with Audience Response

Learning Objectives:

• Apply an evidenced-based approach to diagnosis of PAH and PH secondary to HF, with a focus on echocardiography vasodilator testing, and right heart catheterization
• Review utilization of right heart catheterization parameters for the diagnosis of PAH
• Employ state-of-the-art evidence-based treatment algorithms to optimize parenteral and oral therapies and assess implications of emerging clinical data for future management plans
• Identify pathogenic mediators of PAH, with a focus on the endothelin and prostacyclin pathways; and appraise implications in terms of treatment targets
• Identify pathophysiologic insights and therapeutic approaches that have evolved in HF that might apply in managing the cardiopulmonary complications of PAH
• List factors to consider in the differential diagnosis of acute decompensated HF and discuss pharmacologic and non-pharmacologic treatment options.

Supported by an educational grant from Actelion

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Chair: David J. Whellan

1:00 PM
Introduction
David J. Whellan

1:05 PM
Background on Heart Failure Device Diagnostics: What Are We Looking At?
J. Thomas Heywood

Learning Objective: Identify potential data elements available from current heart failure devices.

1:25 PM
Clinical Trial Results Overview: When Have Diagnostics Been Evaluated?
Philip B. Adamson

Learning Objective: Describe how to integrate the data into the every day management of heart failure.

1:45 PM
Implementation in Clinical Practice: How Can This Information Be Used Now?
Nancy B. Albert

Learning Objective: Define what changes in heart failure diagnostic data are predictive of clinical events.

2:05 PM
The Future of Diagnostics: Where Are We Going?
Gregg C. Fonarow

Learning Objective: Discuss the current level of evidence for the use of diagnostic and future trends in diagnostics.

2:25 PM
Case Studies with Panel Discussion
Faculty

2:50 PM
Questions and Answers

Supported by an educational grant from Medtronic

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderator: Walter J. Koch

3:15 PM
Nuclear Receptor Signaling
The 4^th Distinguished Lecture in Basic Science
Ronald Evans

(Award to be presented immediately following lecture)

4:00 PM^*
SR Modulating Proteins
Evangelia G. Kranias

4:30 PM^*
GSK-3 Regulates β-Adrenergic Responsiveness, Post-MI Remodeling, and Cardiomyocyte Proliferation
Thomas Force

5:00 PM^*
T-type Calcium Channels and Cardiac Function
Steven R. Houser

5:30 PM^*
Cardiac Stem Cells
Mark A. Sussman

^* 25 minute presentation, 5 minute audience questions

Learning Objective: Describe current knowledge about nuclear receptor signaling, SR modulating proteins, GSK3α, T-type calcium channels, and cardiac stem cells and their role in heart failure and heart failure treatment.

Chair: G. Michael Felker

4:00 PM
Welcome and Introduction
G. Michael Felker

4:10 PM
Pathophysiology of the Cardio-Renal Syndrome in Heart Failure
John C. Burnett, Jr.

Learning Objective: Discuss the pathophysiology of worsening renal function in heart failure, including the role of congestion, neurohumoral activation, natriuretic peptides, and renal injury.

4:30 PM
Questions and Answers

---

4:35 PM
Hyponatremia in Heart Failure: Pathophysiology, Clinical Implications and Treatment Options
James E. Udelson

Learning Objective: Discuss the pathophysiology of hyponatremia in heart failure, its clinical implications, and therapeutic options.

4:55 PM
Questions and Answers

---

5:00 PM
Implications of Emerging Renal Biomarkers for Heart Failure Management
James L. Januzzi

Learning Objective: Describe emerging biomarkers of renal function and injury such as Cystatin C and NGAL and their potential clinical uses in the management of patients with heart failure.

5:20 PM
Questions and Answers

---

5:25 PM
Worsening Renal Function in ADHF: Marker or Mediator?
John R. Teerlink

Learning Objective: Discuss epidemiologic data linking worsening renal function (WRF) to outcomes in heart failure, and discuss impact of recent clinical trials (e.g., PROTECT, DOSE) on the current understanding of the importance of WRF. Discuss potential therapeutic options for preventing or treating WRF in patients with ADHF.

5:45 PM
Questions and Answers

5:50 PM
Panel Discussion and Final Remarks

Supported by an educational grant from Otsuka America Pharmaceuticals

This satellite program is not part of the scientific program as planned by the Heart Failure Society of America Program Committee.

Moderators: Douglas L. Mann
                  Christopher M. O'Connor

8:30 AM
Nanotechnology and its Application to Cardiovascular Disease: Microsystems for Disease Evaluation
Nan Marie Jokerst

8:55 AM
Comparative Genomics and Human Disease: Some Recent Contributions From Zoos
Oliver A. Ryder

9:20 AM
Personalized Medicine: From Theory to Practice
Ralph Snyderman

9:45 AM
Panel Discussion

Learning Objective: Describe new technologies and disease models in heart failure.

Moderators: Carl V. Leier
                   Marc A. Pfeffer

10:30 AM^*
CUPID 1: MYDICAR® in Patients with Advanced Heart Failure Continue To Show Significant Improvement in Clinical Outcomes Compared to Optimal Therapy 9 Months Post-Dose
Barry H. Greenberg, University of California, San Diego, CA

Commentary: Michael R. Bristow

10:48 AM^*
NEXT-HEART Tai Chi Exercise Improves Quality of Life in Patients With Chronic Heart Failure in Randomized Controlled Trial
Gloria Yeh, Beth Isreal Deaconess Medical Center, Boston, MA

Commentary: Ileana L. Piña

11:06 AM^*
Economic Impact of Monitoring Heart Transplant Recipients with Gene Expression Profiling to Detect Rejection: An IMAGE Analysis
Paul A. Heidenreich, VA Palo Alto Health Care System, Palo Alto, CA

Commentary: Mandeep R. Mehra

11:24 AM^*
Ventricular Elastic Support Therapy (VEST) in Stage C Heart Failure: Analysis from the PEERLESS-HF Study
William T. Abraham, The Ohio State University, Columbus, OH

Commentary: Eric J. Velazquez

11:42 AM^*
The PEARL-HF (Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multiple-Dose To Evaluate the Effects of RLY5016 in Heart Failure Patients) Trial
Bertram Pitt, University of Michigan, Ann Arbor, MI

Commentary: Milton Packer

^* 18 minutes allotted: 10 minute presentation, 5 minute commentary, 3 minutes for audience questions

Learning Objective: Describe the results of recent trials and discuss their implications for the care of patients with heart failure.

Moderators: Kathleen A. Dracup
                   Mariann R. Piano

10:30 AM^*
Impact of Caregiving on Family Caregivers of Patients with Heart Failure
Boyoung Hwang

10:48 AM^*
Cognitive Impairment Patterns in Chronic Heart Failure
Lisa C. Bauer

11:06 AM^*
Trends in Dyspnea Predict 12-Month Outcomes in Patients with Heart Failure
Tsuey-Yuang Huang

11:24 AM^*
Heart Failure Disease Management: Will It Reduce the Incidence of Device Shocks?
Tamra L. Ward

11:42 AM^*
Quality of Life is Improved in Uninsured Heart Failure Patients in Disease Management Programs in Public Hospitals
Aurelia Macabasco-O’Connell

^* 10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss the results of recent nursing research and their implications for the care of patients with heart failure.

Moderators: Inder S. Anand
                   Eugene Braunwald

10:30 AM^*
Partial Recovery of Myocyte Contractile Function with Left Ventricular Assist Device Support in Patients with Nonischemic Cardiomyopathy
Amrut V. Ambardekar

10:48 AM^*
Right Ventricular and Pulmonary Vascular Response Patterns to Exercise Predict Exercise Capacity and Outcomes in Heart Failure
Gregory D. Lewis

11:06 AM^*
Ventricular Assist Device Implantation Corrects Myocardial Lipotoxicity, Reverses Insulin Resistance and Normalizes Cardiac Metabolism in Advanced Heart Failure
P. Christian Schulze

11:24 AM^*
The Novel Dual Natriuretic Peptide Receptor Activator CD-NP Decreases Fibrosis and Improves Diastolic Dysfunction Produced by Mild Renal Insufficiency
Fernando L. Martin

11:42 AM^*
A Genetic Variant of the ANP Gene is Associated with a Lower Cardiometabolic Risk Profile in the General USA Population
Valentina Cannone

^* 10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss the results of recent research and discuss their implications for the care of patients with heart failure.

Moderators: William S. Colucci
                   Hani N. Sabbah

10:30 AM^*
Myocardial Recovery is Associated with Molecular Hysteresis In a Model of Conditional Transgenesis
Veli K. Topkara

10:48 AM^*
The Pharmacokinetics of Molecular Cardiac Surgery with Recirculating Delivery (MCARD™) Results in Robust Cardiac-Specific βARKct Gene Delivery to Ovine Myocardium
Anthony S. Fargnoli

11:06 AM^*
Clinical Heterogeneity of Cardiomyocytes Due to Mutations in Myopalladin Gene
Enkhsaikhan Purevjav

11:24 AM^*
Loss of PHD Prolyl Hydroxylase Activityin Cardiomyocytes Phenocopies Ischemic Cardiomyopathy
Javid Moslehi

11:42 AM^*
Growth Hormone Releasing Hormone Agonist Improves Cardiac Performance in the Chronic Model of Myocardial Infarction (MI) In Rats
Rosemeire M. Kanashiro-Takeuchi

^* 10 minute presentation, 8 minute audience discussion

Learning Objective: Discuss results and implications of basic science research in heart failure.

1. How to Prevent Heart Failure
   Carla S. Dupree, Mark A. Winchester


Learning Objective: Implement strategies to prevent the development of heart failure.


2. How to Transition From Hospital to Home
   Kathryn H. Bowles, Paul A. Heidenreich


Learning Objective: Effectively transition patients with heart failure from hospital to home using patient-centered care strategies.


3. How to Evaluate Supplements and Noncardiac Drug Interactions in Heart Failure Patients
   Alan B. Miller, Mark A. Munger


Learning Objective: Counsel patients with heart failure on their use of supplements and identify potential supplement-drug interactions.


4. How to Manage LVAD Complications
   Carmelo A. Milano, James C. Fang, D. Eric Steidley


Learning Objective: Anticipate potential complications in patients with LVADs and employ effective strategies in their management.


5. How to Manage Peripartum Cardiomyopathy
   Uri Elkayam, Dennis M. McNamara


Learning Objective: Manage patients with peripartum cardiomyopathy using evidence-based therapies.


6. How to Do Site-Based Research Including Securing Research Grants for Your Heart Failure Practice
   Patricia A. Adams, George Sopko


Learning Objective: Develop a plan for site-based heart failure research and the submission of effective grant proposals.

Moderators: Horng H. Chen
                  David E. Lanfear

12:30 PM^*
Chronic Rapamycin Therapy Ameliorates Hypertrophy and Systolic Dysfunction in Severe Chronic Heart Failure Due to Pressure Overload
Kalkidan Bishu

12:45 PM^*
Loss of PI3Kγ Enhances cAMP-Dependent MMP Remodeling of N-Cadherin Adhesion Complexes and Extracellular Matrix in Response to Biomechanical Stress
Danny Guo

1:00 PM^*
Myocardial Pronatriuretic Peptide Convertase Furin in the Presence and Absence of Experimental Heart Failure
Tomoko Ichiki

1:15 PM^*
The Right Ventricular Hypertrophic Response Does Not Mirror the Left Ventricle
Sushma Reddy

^* 10 minute presentation, 5 minute audience discussion

Learning Objective: Discuss the results of recent heart failure research bridging the gap between basic science and clinical care.

Moderator: Leslie A. Saxon

2:00 PM
Pharmacotherapy for Atrial Fibrillation in Heart Failure Patients
Prakash C. Deedwania

2:20 PM
Anticoagulation in AF with CHF Patients
Richard G. Becker

2:40 PM
Managing AF in Heart Failure: Role of Catheter Ablation
J. Marcus Wharton

3:00 PM
Registries in Atrial Fibrillation: What Do They Tell Us?
Gregg C. Fonarow

3:20 PM
Panel Discussion

Learning Objective: Describe the roles of catheter ablation, pharmacotherapies, and anticoagulation in the management of AF in patients with heart failure.

Moderator: John C. Burnett, Jr.

2:00 PM^*
Risk Stratification with Biomarkers: Individual or Multimarker Panels?
James L. Januzzi

2:18 PM^*
Transcriptomics in Heart Failure: Translational Science and Clinical Applications
Thomas P. Cappola

2:36 PM^*
The Use of Biomarkers in Clinical Trials
G. Michael Felker

2:54 PM^*
Pharmacogenetic Discovery in Clinical Trials
Michael R. Bristow

3:12 PM^*
Integration of Omics
Stephen B. Liggett

^* 15 minute presentations, 3 minute discussion

Learning Objective: Discuss the potential use of biomarkers in heart failure research and risk stratification and recent developments in personalized medicine.

Moderator: Roger J. Hajjar

2:00 PM
Decellularized Natural Matrix for Cardiac Organ Engineering
Doris A. Taylor

2:20 PM
Biologically Inspired Injectable Matrix for Cardiac Tissue Engineering
Karen L. Christman

2:40 PM
Engineered Cardiac Tissues for In Vitro Evaluation of Myocardial Repair Strategies
Kevin Costa

3:00 PM
Engineered Substrates for Controlling Cardiodmyocyte Remodeling In Vitro
Kevin Kit Parker

3:20 PM
Panel Discussion

Learning Objective: Describe current knowledge and practice in cardiac tissue engineering for research and myocardial repair.

Moderator: Kenneth B. Margulies

2:00 PM
Biology of Aging in the Cardiac Patient
Bodh I. Jugdutt

2:20 PM
Aging and Diastolic Heart Failure
Jerome L. Fleg

2:40 PM
How to Assess Frailty in the Elderly
Dalane W. Kitzman

3:00 PM
Pharmacotherapy in the Elderly
Michael W. Rich

3:20 PM
Panel Discussion

Learning Objective: Effectively manage elderly patients with heart failure, including those with preserved EF, mindful of complications such as frailty.

Moderator: Shey-Shing Sheu

2:00 PM^*
Plasma Membrane CA²⁺ Signaling
Mark E. Anderson

2:22 PM^*
Novel Targets to Modulate SR CA²⁺ Signaling
Patrick Most

2:44 PM^*
Mitochondrial CA²⁺ Signaling and Myocyte Death
Roberta A. Gottlieb

3:07 PM^*
Nuclear Calcium and Hypertrophic Gene Regulation
Donald M. Bers

^*20 minute presentation, 2-3 minutes audience discussion

Learning Objective: Describe current research in calcium signaling and the role of calcium signaling in heart failure.

Moderators: JoAnn Lindenfeld
                   Randall C. Starling

4:00 PM
Evaluation of Patients for Ventricular Dysfunction and Heart Failure
W.H. Wilson Tang

4:12 PM
Management of Asymptomatic Patients with Reduced Left Ventricular Ejection Fraction
W.H. Wilson Tang

4:15 PM
Questions and Comments

4:25 PM
Heart Failure in Patients with Left Ventricular Systolic Dysfunction
Justin A. Ezekowitz

4:40 PM
Questions and Comments

4:50 PM
Evaluation and Management of Patients with Acute Decompensated Heart Failure
Sean P. Collins

5:05 PM
Questions and Comments

5:15 PM
Panel Discussion and Questions
Nancy J. Albert, Sean P. Collins, Justin A. Ezekowitz, J. Herbert Patterson, W.H. Wilson Tang

Learning Objective: Identify changes in practice recommendations and implement them in the care of patients with heart failure.

Moderator: John P. Boehmer

4:00 PM
Epidemiology and Risk Stratification of Sudden Death
Alfred E. Buxton

4:20 PM
Pharmacotherapy of VT
Leslie A. Saxon

4:40 PM
Device Therapy and Ablative Strategies for VT Management
James P. Daubert

5:00 PM
ICD Shocks Lead to Heart Failure
Bruce L. Wilkoff

5:20 PM
Panel Discussion

Learning Objective: Describe pharmacologic, device, and ablative treatment options for VT and the role of VT in the sudden death of patients with heart failure.

Moderator: Thomas Force

4:00 PM
Dilated Cardiomyopathy Genes: 30+ and Counting
Ray E. Hershberger

4:20 PM
Clinical Perspective in HCM
Elizabeth M. McNally

4:40 PM
Myosin-Binding Protein C and HCM
Jeffery Robbins

5:00 PM
Functional Genomics in HCM Patients
Gerald W. Dorn, II

5:20 PM
Panel Discussion

Learning Objective: Describe the role of genetics in the diagnosis and treatment of hypertrophic cardiomyopathy.

Moderator: Kirk U. Knowlton

4:00 PM^*
Drosophila as a Model of Heart Disease and Aging
Rolf Bodmer

4:22 PM^*
Genetic Screens for Identifying Cardiomyopathy Genes
Matthew J. Wolf

4:45 PM^*
Zebrafish as a Model of Cardiovascular Disease
Didier Y.R. Stainier

5:07 PM^*
Cardiac Regeneration Using Zebrafish as a Model
Kenneth D. Poss

^* 20 minute presentation, 2-3 minute audience discussion

Learning Objective: Discuss model organisms being used for research in cardiomyopathy and aging.

Moderator: Mihai Gheorghiade

8:30 AM
The Emergency Department Perspective
Peter S. Pang

8:42 AM
The Cardiologist's Perspective
Mihai Gheorghiade

8:54 AM
Regulatory Perspectives on Dyspnea - FDA
Norman L. Stockbridge

9:08 AM
Industry's Perspective on Dyspnea
Roger M. Mills

9:20 AM
Dyspnea as an Endpoint in Acute Heart Failure Trials
John R. Teerlink

9:35 AM
Panel Discussion

Learning Objective: Outline the pros and cons of using dyspnea as a critical endpoint in acute heart failure trials.

Moderator: Burns C. Blaxall

8:30 AM
Vasoactive Peptide Signaling and Vascular Control
R. Clinton Webb

8:50 AM
Stretch and Cardiac Hypertophy via β-Arrestin Signaling
Howard A. Rockman

9:10 AM
Cardiovascular Predictors of Hypertension Progression and Disease Outcomes
Eric J. Velazquez

9:30 AM
Treating the Hypertensive Heart Failure Patient
Jonathan G. Howlett

9:50 AM
Panel Discussion

Learning Objective: Describe selected microbiological determinant of hypertension, cardiovascular predictors of disease progression, and treatment options for the patient with heart failure and hypertension.

Moderator: Bertram Pitt


8:30 AM
Epidemiology and Pathophysiology of Stage B Heart Failure: Insights From SOLVD Prevention 30 Years Later
Barry H. Greenberg

9:00 AM
Post MI to Heart Failure
Scott D. Soloman

9:15 AM
Diabetes to Heart Failure
Javed Butler

9:30 AM
Obesity to Heart Failure
Stefan D. Anker

9:45 AM
Panel Discussion

Learning Objective: Implement strategies to prevent the progression of disease in patients with Stage B heart failure.

Moderators: Kanu Chatterjee
                   G. Michael Felker

8:30 AM
Is The Physical Exam Useful in Following Patients?
Eldrin F. Lewis

8:45 AM
Biomarkers: Do We Need Anything Else?
W.H. Wilson Tang

9:00 AM
Imaging: When and How Often
Ayan R. Patel

9:15 AM
Implantable Monitoring Devices: Can We Throw Away The Stethoscope?
William T. Abraham

9:30 AM
When Do We Stop Monitoring and Therapy?
David J. Whellan

9:45 AM
Panel Discussion

Learning Objective: Use the physical exam, biomarkers, and other strategies to monitor patients with heart failure, discontinuing therapy as warranted.

Moderator: Federica del Monte

8:30 AM^*
MicroRNAs and Cardiac Hypertrophy
Gianluigi Condorelli

8:52 AM^*
CaMKII in Cardiac Stress and Ischemic Responses
Joan Heller Brown

9:15 AM^*
Cardiac Ncx-1 Gene Regulation by HDACs and Nkx2.5
Donald R. Menick

9:38 AM^*
Proteome Biology of Cardiac Mitochondria: One Protein Land Governed by Two Genomes
PeiPei Ping

^* 20 minute presentation, 2-3 minute audience discussion

Learning Objective: Describe current research related to hypertrophic gene transcription.

Moderator: Lynne Warner Stevenson

Panelists:
J. Malcolm O. Arnold
John Chin
Sharon A. Hunt
Camelo A. Milano
Patricia A. Uber
Kismet D. Rasmusson
Bruce L. Wilkoff

10:30 AM
Case 1

10:52 AM
Case 2

11:14 AM
Case 3

11:37 AM
Case 4

Learning Objective: Using practice guidelines, research findings, and clinical experience, make decisions about the management of difficult cases in heart failure.

Moderator: Mary N. Walsh

10:30 AM
Adherence and Literacy: How Can We Do Better?
Nancy Houston-Miller

10:45 AM
Activity and Exercise: What Is the Right Activity Prescription?
Ileana L. Piña

11:00 AM
Stress Management with Biofeedback
Christine S. Moravec

11:15 AM
Managing Salt in the Diet
Terrie A. Lennie

11:30 AM
Managing Dietary Salt: A Public Health Dilemma
Kirsten Bibbins-Domingo

11:45 AM
Panel Discussion

Learning Objective: Use effective patient education strategies to improve medication adherence, exercise, and stress management.

Moderators: David DeNofrio
                   Soon J. Park

10:30 AM
Biology of LV Recovery Following LVAD
Michael A. Acker

10:50 AM
Risk Stratification for Patient Selection for LVAD Therapy
Wayne C. Levy

11:10 AM
Pulsatile vs. Nonpulsatile Flow Devices: Lessons Learned From INTERMACS and Clinical Trials
Joseph G. Rogers

11:30 AM
Can We Afford to Use Mechanical Devices for Heart Failure?
Daniel B. Mark

11:50 AM
Panel Discussion

Learning Objective: Describe the biology of LV recovery following LVAD, effective strategies for risk stratification, the pros and cons of pulsatile vs. nonpulsatile devices, and the economics of LVAD use.

Moderator: Wolfgang H. Dillmann

10:30 AM
Nuclear Receptor Signaling and Heart Failure
Daniel P. Kelly

10:50 AM
Adiponectin as a Cardioprotective Factor
Kenneth Walsh

11:10 AM
AMPK Activity in the Failing Heart
Rong Tian

11:30 AM
Insulin Signaling in Cardiomyopathy
Anthony Rosenzweig

11:50 AM
Panel Discussion

Learning Objective: Discuss the role of metabolic pathways in the pathogenesis and potential treatment of heart failure.

Moderator: Anthony J. Muslin

10:30 AM^*
The APJ/Apelin Signaling Complex in Cardiac Hypertrophy and Failure
Pilar Ruiz-Lozano

10:52 AM^*
GSK3-β and Cardiac Hypertrophy and Failure
Junichi Sadoshima

11:14 AM^*
Pathological PAR-1 Signaling in the Heart by Both Direct Activation and Transactivation
Burns C. Blaxall

11:37 AM^*
Adenosine Receptors and Cardiac Hypertrophy and Failure
Arthur M. Feldman

^* 20 minute presentation, 2-3 minute audience discussion

Learning Objective: Discuss the role of cardiomyocyte signaling in cardiac hypertrophy and failure.

7. How to Manage Dyslipidemia and Heart Failure?
   Javed Butler, Nancy Houston-Miller


Learning Objective: Managing the patient with heart failure and dyslipidemia.


8. How to Incorporate Existing and New Performance Measures Into Your Practice: What Do They Mean For Your Practice?
   Rebecca L. Angerstein, Paul J. Hauptman


Learning Objective: Incorporate current and new performance measures into your management of patients with heart failure.


9. How to Choose and Optimize Device Therapy in Your Heart Failure Patient
   Paul J. Mather, Leslie W. Miller


Learning Objective: Use guidelines, trial evidence, and clinical experience to select patients for device-based heart failure therapy.


10. How to Use Genetics and Biomarkers in Your Outpatient Heart Failure Clinic
    Mona Fiuzat, Ray E. Hershberger, Margaret M. Redfield


Learning Objective: Describe the effective use of genetics and biomarkers in the outpatient diagnosis and treatment of heart failure.


11. How to Treat Mitral Regurgitation in Systolic Heart Failure
    Tamara B. Horwich, Ayan R. Patel


Learning Objective: Use evidence-based treatment strategies to manage your patients with heart failure and mitral regurgitation.


12. How to Assess Invasive and Noninvasive Hemodynamic Measurements
    J. Thomas Heywood, Michael A. Mathier

Learning Objective: Describe the effective assessment of invasive and noninvasive hemodynamic measurements in heart failure.

Moderators: Justin A. Ezekowitz
                   Peter P. Liu

12:30 PM^*
Pecutaneous Left Ventricular Partitioning for Ischemic Heart Failure: Results of the US-PARACHUTE Feasibility Study
William T. Abraham, The Ohio State University, Columbus, OH

12:45 PM^*
Randomized Trial of Aldosterone AntagonisM in Diastolic Heart Failure (RAAM-DHF)
Anita Deswal, VA Medical Center &Baylor College of Medicine, Houston, TX

1:00 PM^*
Serum 24-Hydroxyvitamin D Concentration: Heart Failure Mortality, and Premature Death From All-Cause in US Adults: An Eight-Year Follow-Up Study
Longjian Liu, Drexel University, Philadelphia, PA

1:15 PM^*
Admission, Discharge, or Change in BNP and Long-Term Mortality: Data from OPTIMIZE-HF Linked with Medicare Claims
Robb Kociol, Duke University, Durham, NC

^* 10 minute presentation, 5 minute audience discussion

Learning Objective: Discuss findings from leading clinical research in heart failure.

Moderators: Douglas D. Shocken
                   Ronald M. Witteles

2:00 PM^* Databases, Predictors, Statistical Modeling: Is the Current Approach To Clinical Research and Medicine Helping or Hurting our Patients?
Barry M. Massie

2:15 PM^* Do Not Call Furosemide a Devil
Maya Guglin

2:30 PM^* Severe Cancer is Heart Failure – Being Cardiologists We Can Become Good Oncologists
Stefan D. Anker

2:45 PM^* How to End the Stage D Heart Failure Ponzi Scheme and Rescue the American Auto Industry
Michael B. Fowler

3:00 PM^* My Mother Wanted Me to Be a Cardiologist Not a VAD Mechanic!!
Mathew S. Maurer

3:15 PM^* What is a Biomarker?
Alan S. Maisel

^* 10 minute presentation, 5 minute audience discussion

Learning Objective: Discuss new insights into the field of heart failure research, education, and clinical practice.

Moderator: Margaret M. Redfield

2:00 PM
Angina in Heart Failure: How Do We Manage?
Eric J. Velazquez

2:20 PM
Sleep Disorders: Does Everyone With Heart Failue Snore?
Stephen S. Gottlieb

2:40 PM
Depression and Heart Failure: Is Diagnosing the Blues Helpful?
Mark D. Sullivan

3:00 PM
Renal Disease and Heart Failure: Cause or Effect?
Michael M. Givertz

3:20 PM
Panel Discussion

Learning Objective: Effectively manage comorbidities, such as angina, sleep disorders, depression, and renal disease in patients with heart failure.

Moderators: Douglas L. Mann
                   Piotr Ponikowski

2:00 PM
Closing the Gap Between Guidelines and Practice
Gregg C. Fonarow

2:25 PM
Clinical Trials, Guidelines, and Performance Measures: Are They as Reliable as We Think They Are?
Jalal K. Ghali

2:50 PM
The Value (and Shortcomings) of Clinical Judgement
Piotr Ponikowski

3:15 PM
Panel Discussion

Learning Objective: Describe the roles of clinical judgement, guidelines, and performance measures in the effective treatment of patients with heart failure.

Moderator: Ju Chen

2:00 PM^*
TWEAK as a Novel Mediator of Cardiac Dysfunction in Heart Failure
Ronglih Liao

2:22 PM^*
Vinculin Abnormalities in the Failing Heart
Robert S. Ross

2:45 PM^*
Novel Phosphatase Activity as a Target in Heart Failure
Yibin Wang

3:07 PM^*
Protease-Dependent Profibrotic Signaling in Cardiac Hypertrophy
Michael R. Zile

^* 20 minute presentation, 2-3 minute audience discussion

Learning Objective: Describe novel participants in cardiomyopathy and heart failure, including TWEAK, vinculin, phosphatase, and proteome biology of cardiac mitochondria.

Moderators: Jay N. Cohn
                   Marvin A. Konstam

DEBATE: LVADs in Class III HF: Should We Be Moving Treatment Upstream?

4:00 PM
Protagonist: Joseph G. Rogers

4:15 PM
Antagonist: Stephen S. Gottlieb

4:30 PM
Questions from Moderators


DEBATE: Should 30-Day Heart Failure Readmission Be a Measure of Quality of Care?

4:45 PM
Protagonist: Gregg C. Fonarow

5:00 PM
Antagonist: Lynne Warner Stevenson

5:15 PM
Questions from Moderators

Learning Objective: Outline arguments for and against the use of LVADs in Class III heart failure and the 30-day admission rate as a quality-of-care measure.

Moderators: Corrine Y. Jurgens

4:00 PM
Neurobiological Basis of Cognitive Changes
Mary A. Woo

4:20 PM
What Are the Best Measures of Cognition in Research and Clinical Practice?
Stephen Moelter

4:40 PM
Cognition and Sleep: Are They Related?
Barbara J. Riegel

5:00 PM
Cognition and Outcomes: Can We Improve Quality of Life?
Susan J. Pressler

5:20 PM
Panel Discussion

Learning Objective: Describe the neurobiological basis of cognitive changes due to heart failure, the measurement of cognitive changes, the relationship of cognition and sleep, and the role of cognition in improved outcomes.

Moderators: Ronglih Liao

4:00 PM
The Clinical Experience with EPC's
Douglas W. Losordo

4:20 PM
A Cellularized Patch for Cardiac Repair
Steven Goldman

4:40 PM
Cardiac Stem Cells and Myocardial Repair
Annarosa Leri

5:00 PM^*
SERCA2a Gene Therapy for Heart Failure
Roger J. Hajjar

5:20 PM
Panel Discussion

Learning Objective: Discuss current applications of stem cell and gene therapy in heart failure treatment.

Moderators: Francisco Villarreal

4:00 PM^*
Fibroblasts in Cardiac Development
Simon J. Conway

4:22 PM^*
The Cardiac Fibroblast: The Renaissance Cell
Troy A. Baudino

4:44 PM^*
New Roles in Fibroblasts in Cardiac Remodeling
Paul A. Insel

5:08 PM^*
Novel Aspects of Cardiac Myocyte to Fibroblast Communication and Clinical Directions
Gregory E. Morley

^* 20 minute presentation, 2-3 minute audience discussion

Learning Objective: Discuss the role of cardiac fibroblasts in cardiac development, disease and remodeling.

Moderators: Kirkwood F. Adams,Jr.
                   Gary S. Francis

8:30 AM^*
Novel Protein Therapeutics for Chronic Systolic Heart Failure: Chronic Subcutaneous BNP Administration (NICE BNP)
Horng H. Chen, Mayo Clinic, Rochester, MN

Commentary: John R. Teerlink

8:48 AM^*
Reducing Decompensation Evens Utilizing IntraCardiac Pressures in Patients with Chronic HF (REDUCEhf)
Philip B. Adamson, Oklahoma Heart Hospital, Oklahoma, OK

Commentary: David J. Whellan

9:06 AM^*
Effects of n-3 Polyunsaturated Fatty Acids (PUFAs) on Left Ventricular Function and Functional Capacity in Patients with Dilated Cardiomyopathy
Savida Nodari, University of Brescia, Brescia, Italy

Commentary: Steven R. Goldsmith

9:24 AM^*
Congestive Heart Failure: A Multidisciplinary Non-Pharmacological Approach for Changing in E-Hospitalization and Prognosis in Patients with Concomitant Anxiety aNd Depression (CHANCE-AND)
Viacheslav Mareev, Russian Society of Heart Failure Specialists, Moscow, Russia

Commentary: Christopher M. O'Connor

9:42 AM^*
CardioMEMS Heart Sensor Allows Monitoring of Pressures to Improve Outcomes in NYHA Class III Heart Failure Patients (CHAMPION) Trial: Impact of Hemodynamic Guided Care on Patients with Preserved Ejection Fraction
Philip B. Adamson, Oklahoma Heart Hospital, Oklahoma, OK

Commentary: Gary S. Francis

^* 18 minutes allotted: 10 minute presentation, 5 minute commentary, 3 minutes for audience questions

Learning Objective: Describe the results of recent trials and their implications for the care of patients with heart failure.

Moderator: Wilson S. Colucci

8:30 AM
Nitroso-Redox Imbalance in Heart Failure
Joshua M. Hare

8:50 AM
Nitric Oxide Enhancement Effects of Hydralazine and Isosorbide Dinitrate on Clinical Outcomes and Ventricular Remodeling
Anne L. Taylor

9:10 AM
Molecular Signaling Significance of Nitrosylation/Denitrosylation
Kenneth R. Laurita

9:30 AM
Nitroxyl (HNO) Donors in Normal and Failing Hearts
Nazareno Paolocci

9:50 AM
Panel Discussion

Learning Objective: Describe the role of nitric oxide in heart failure and the effects of nitric oxide enhancement on ventricular remodeling and clinical outcomes.

Moderators: Terry A. Lennie

8:30 AM
Utilizing Family to Improve Dietary Adherence
Carolyn M. Reilly

8:50 AM
How Do Interventions with Patients Affect Caregiver Outcomes?
Misook L. Chung

9:10 AM
Interactions With Other Specialists: Coordinating the Medical Home From The Heart Failure Clinic
Mary N. Walsh

9:30 AM
End-of-Life: Transitioning to Palliative Care
Larry A. Allen

9:50 AM
Panel Discussion

Learning Objective: Describe treatment strategies in the medical home model and how they impact the patient and caregivers.

Moderator: Teresa De Marco

8:30 AM
Update on Pulmonary Arterial Hypertension (PAH): From Drugs to Lifestyle Modifications
Michael A. Mathier

8:50 AM
PAH in Valvular Disease: Do Pulmonary Vasodilators Help?
Myung H. Park

9:10 AM
Pulmonary Hypertension in Systolic Heart Failure: Implications and Management
Srinivas Murali

9:30 AM
PAH and Diastolic Dysfuntion: Can We Use Vasoactive Therapies?
Marc J. Semigran

9:50 AM
Panel Discussion

Learning Objective: Describe current treatment options for patients with pulmonary arterial hypertension.

Moderators: Milton Packer
                   Norman L. Stockbridge

10:30 AM
I PRESERVE
Peter E. Carson

10:50 AM
SENIORS
Andrew J.S. Coats

11:10 AM
EVEREST: Vasopressin Antagonists
Mihai Gheorghiade

11:30 AM
PROTECT: Adenosine Antagonists
Christopher M. O'Connor

11:50 AM
Overview
Milton Packer

Learning Objective: Outline findings of selected clinical trials and their implications for heart failure treatment.

Moderator: Mariell L. Jessup

10:30 AM
Patient Selection and Risk Stratification
Donna M. Mancini

10:45 AM
Understanding Common Immunosuppression Strategies
Jon A. Kobashigawa

11:00 AM
Monitoring of Post-Transplant Patients: Invasive, Noninvasive and Molecular Strategies
Stuart D. Russell

11:15 AM
Cardiac Allograft Vasculopathy
Randall C. Starling

11:30 AM
Pyschocial Disorders and Distress After Cardiac Transplantation
Katherine J. Hoercher

Learning Objective: Discuss patient selection and risk stratification for transplantation, immunosuppression, monitoring, and the role of cardiac allograft vasculopathy.

Moderators: Hector O. Ventura

10:30 AM
Hypertrophic Cardiomyopathy
Tamara B. Horwich

10:50 AM
Noncompaction Cardiomyopathy
Euan A. Ashley

11:10 AM
Amyloid Cardiomyopathy
Mathew S. Mauer

11:30 AM
The Athlete and Cardiomyopathy: Can They Play Ball?
James P. Daubert

11:50 AM
Panel Discussion

Learning Objective: Diagnose and manage hypertrophic, noncompaction, and amyloid cardiomyopathy and cardiomyopathy in the athlete.

Moderators: Nancy M. Albert

10:30 AM
The Spectrum of the Problem
Barry M. Massie

10:50 AM
Environmental and Social Reasons for Readmission
Debra K. Moser

11:10 AM
The CMS Report Card: Why Did Your Hospital Receive an "F"
Paul A. Heidenreich

11:30 AM
Disparities in Readmission: Are We Addressing The Real Problem?
David J. Whellan

11:50 AM
Panel Discussion

Learning Objective: Describe causes for heart failure readmissions and procedures for hospital evaluation.